28/07/2014 14:34:39 Free Membership Login

Nymox Pharmaceutical News (NASDAQ:NYMX)

DateTimeSource
Headline
07/22/20149:30AMGLOBENymox Announces Positive Efficacy Results in Phase 3 Repeat Injection Trial of NX-1207 for BPH
HASBROUCK HEIGHTS, N.J., July 22, 2014 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to announce new positive efficacy data for U.S. Study NX02-0022, the Company's repeat injection study of NX-1207 for BPH. Analysis of symptomatic improvement from repeat injection over a 1 to 2 year period... More...>>
07/15/20149:30AMGLOBENymox Announces Completion of Enrollment for Second BPH Re-Injection Study
HASBROUCK HEIGHTS, N.J., July 15, 2014 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today the closing of enrollment for Study NX02-0022, the Company's second re-injection Phase 3 clinical trial of the safety and efficacy of NX-1207 for the treatment of enlarged prostate (benign prostatic... More...>>
06/17/201410:00AMGLOBENymox Reports Positive Update on Nerve Sparing and Sexual Function Preservation in Men Treated With NX-1207
HASBROUCK HEIGHTS, N.J., June 17, 2014 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to report new data supporting the positive sexual functional preservation profile of NX-1207, the Company's lead compound in Phase 3 development for the treatment of prostate enlargement (BPH or benign prostatic... More...>>
06/11/201410:15AMGLOBENymox Reports Positive New Safety Study Data for Phase 3 BPH Drug
HASBROUCK HEIGHTS, N.J., June 11, 2014 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to announce new clinical data supporting the positive safety profile of NX-1207, the Company's lead compound in late Phase 3 testing for prostate enlargement (BPH or benign prostate hyperplasia). Recent... More...>>
05/21/20149:50AMGLOBENymox Reports New Results on Favorable Side Effect Profile of NX-1207 Treatment
HASBROUCK HEIGHTS, N.J., May 21, 2014 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to report new positive data confirming the advantageous side effect profile of the Company's lead compound NX-1207. Results from the Brief Male Sexual Function Questionnaire (BMSF) in the Company's recently... More...>>
05/15/20149:45AMGLOBENymox Reports First Quarter 2014 Financial Results
HASBROUCK HEIGHTS, N.J., May 15, 2014 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today its financial results for the first quarter of 2014. Nymox reported a net loss of $2,592,816, or $0.07 per share for the quarter ended March 31, 2014, compared to $1,093,906, or $0.03 per share for the... More...>>
05/13/20149:45AMGLOBENymox Reports Positive Results Showing That NX-1207 Treatment for Prostate Cancer Does Not Affect Testosterone Levels
HASBROUCK HEIGHTS, N.J., May 13, 2014 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) reported today positive new study findings showing that the Company's NX-1207 Phase 2 treatment for localized low-risk prostate cancer did not affect testosterone levels in treated men. Analysis of testosterone levels... More...>>
05/08/201410:30AMGLOBENymox Announces Completion of Second Pivotal Phase 3 NX-1207 Trial for BPH
HASBROUCK HEIGHTS, N.J., May 8, 2014 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today that the last enrolled patient has completed participation in the Company's pivotal Phase 3 clinical trial, NX02-0018. The NX02-0018 trial is the second of two pivotal prospective double blind placebo-controlled... More...>>
05/06/201410:00AMGLOBENymox Announces Positive New Prostate Cancer Clinical Trial Results
HASBROUCK HEIGHTS, N.J., May 6, 2014 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today new positive outcome results from the Company's ongoing prospective trial of NX-1207 for the treatment of low grade localized prostate cancer. These are the first clinical patient treatment outcome results... More...>>
04/30/20149:30AMGLOBENymox Reports Top-Line Results for Localized Prostate Cancer Study
HASBROUCK HEIGHTS, N.J., April 30, 2014 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to report top-line results from the company's 146 patient NX03-0040 Phase 2 U.S. prostate cancer study. The results from the study indicate an overall benefit in terms of reduced progression in patients... More...>>
03/14/20141:00PMGLOBENymox Reports 2013 Financial Results
HASBROUCK HEIGHTS, N.J., March 14, 2014 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today its financial results for the year ended December 31, 2013 prepared in accordance with International Financial Reporting Standards. Nymox reported a net loss of $4,908,603, or $0.14 per share for the... More...>>
02/05/20142:00PMGLOBENymox Announces Appointment of Andre Monette
HASBROUCK HEIGHTS, N.J., Feb. 5, 2014 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to announce the appointment of Andre Monette as Chief Financial Officer of the Company. Mr. Monette, who is a Chartered Professional Accountant and Chartered Financial Analyst, brings to the company extensive... More...>>
01/28/201411:30AMGLOBENymox Provides Update on NX-1207 Phase 3 BPH and Phase 2 Prostate Cancer Clinical Trial Activities
HASBROUCK HEIGHTS, N.J., Jan. 28, 2014 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) today provided updates on pivotal Phase 3 development activities for NX-1207, the Company's Phase 3 drug for benign prostatic hyperplasia (BPH), a common affliction of older men. NX-1207 is also in development in Phase... More...>>
01/13/201410:00AMGLOBENymox Closes Recruitment for NX-1207 Phase 2 Prostate Cancer Trial
HASBROUCK HEIGHTS, N.J., Jan. 13, 2014 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) today announced that recruitment is being closed for the Company's Phase 2 study of NX-1207 for low risk localized prostate cancer (NX03-0040) and that enrollment will be formally completed shortly. Initial top line... More...>>
11/14/201310:15AMGLOBENymox Reports Third Quarter 2013 Financial Results
HASBROUCK HEIGHTS, N.J., Nov. 14, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today its financial results for the third quarter of 2013. Nymox reported a net loss of $1,020,387, or $0.03 per share, for the quarter and $3,591,682, or $0.11 per share, for the nine months ended September... More...>>
11/11/201311:45AMGLOBENymox Reports Update and Positive Safety Data for Phase 3 NX02-0022 Reinjection Study of NX-1207 for BPH
HASBROUCK HEIGHTS, N.J., Nov. 11, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) reported a favorable update and recent Safety Monitoring Committee review of safety data for the Company's NX02-0022 reinjection study for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia (BPH... More...>>
09/26/20139:45AMGLOBENymox Prostate Cancer Drug Treatment Trial Nears Completion
HASBROUCK HEIGHTS, N.J., Sept. 26, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today that enrollment in the company's NX03-0040 US Phase 2 clinical trial of NX-1207 for localized prostate cancer is nearing completion with over 80% patients now enrolled. Based on current screening and... More...>>
08/22/201310:15AMGLOBENymox Reports Positive Results of Safety Monitoring Committee Review of NX02-0018 Phase 3 Trial
HASBROUCK HEIGHTS, N.J., Aug. 22, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) reported favorable results from the most recent Safety Monitoring Committee periodic review of safety data for the Company's NX02-0018 clinical trial, one of the two Phase 3 pivotal trials for NX-1207, Nymox's investigational... More...>>
08/14/201310:00AMGLOBENymox Reports Second Quarter 2013 Financial Results
HASBROUCK HEIGHTS, N.J., Aug. 14, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today its financial results for the second quarter of 2013. Nymox reported net losses of $1,477,389, or $0.04 per share, for the quarter and $2,571,295, or $0.08 per share, for the six months ended June 30... More...>>
07/11/201312:45PMGLOBENymox Reports Positive Safety Monitoring Committee Results for Pivotal NX02-0017 Phase 3 Trial
HASBROUCK HEIGHTS, N.J., July 11, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) reported favorable results from the most recent Safety Monitoring Committee review of ongoing safety data for the Company's NX02-0017 clinical trial, one of the two Phase 3 pivotal trials for NX-1207, Nymox's investigational... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nasdaq nymx140728 14:34